Vericel скачать в хорошем качестве

Vericel

Ross Tubo, Ph.D., Chief Scientific Officer Cambridge, MA (NASDAQ: VCEL) Vericel Corporation (formerly Aastrom Biosciences) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The Company markets two cell therapy products in the U.S., Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns comprising greater than or equal to 30% of total body surface area. Vericel is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (DCM). www.vcel.com